{"preliminary_commentary":{"by_channel":{"x_thread":69,"youtube":5,"podcast":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01526135\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["mFOLFIRINOX"]],"indication":"resected pancreatic adenocarcinoma","name":"PRODIGE 24","nct_id":"NCT01526135","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=prodige-24-nct01526135. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Arm A : Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks","label":"Arm A GEMCITABINE","type":"ACTIVE_COMPARATOR"},{"description":"Arm B : mFOLFIRINOX every 14 days, 12 cycles, 24 weeks. Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.\n\nFolinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.\n\n5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)","label":"Arm B mFOLFIRINOX","type":"EXPERIMENTAL"}],"collaborators":["Canadian Cancer Trials Group"],"completion_date":{"date":"2021-07-16","type":"ACTUAL"},"conditions":["Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)"],"enrollment":{"count":493,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"mFolfirinox","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"}],"last_update":"2022-01-04","lead_sponsor":"UNICANCER","official_title":"Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2018-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"disease-free survival (DFS)","timeFrame":"3 YEARS"}],"references":[{"citation":"Witz A, Conroy T, Lambert A, Salleron J, Diallo A, Husson M, Nicolle R, Hammel P, Biagi J, Renouf DJ, Turpin A, Richard C, Bachet JB, Iovanna J, Dusetti N, Monard L, Mauduit M, Cros J, Harle A. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. J Clin Oncol. 2026 Sep 10;44(26):2517-2528. doi: 10.1200/JCO-25-02508. Epub 2026 Aug 3.","pmid":"42546248","type":"DERIVED"},{"citation":"Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouche O, Monard L, Lambert A, Hammel P; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829.","pmid":"36048453","type":"DERIVED"},{"citation":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Chone L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.","pmid":"30575490","type":"DERIVED"}],"start_date":{"date":"2012-04-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT01526135"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/prodige-24-nct01526135"}